Addressing Important Unmet Clinical Needs in Corneal Health
Glaukos’ acquisition of Avedro combines two complementary, hybrid pharmaceutical and device ophthalmic organisations and establishes the cornerstone for Glaukos’ new corneal health franchise.
Avedro’s platform uses its proprietary, bio-activated, single-use Photrexa® drug formulations to strengthen corneal tissue and halt progression of keratoconus, a degenerative corneal ectatic disease that affects approximately 1.1 million eyes in the United States. Typically diagnosed in a patient’s teenage years, keratoconus is characterised by progressive thinning and weakening of the cornea, resulting in vision loss. Approximately 90% of cases are bilateral and as many as 20% of patients ultimately require a corneal transplant. Conventional treatments address symptoms but the Avedro platform is the first and only FDA-approved therapy that has been shown to stop disease progression.
Avedro has also developed a pipeline of novel single application bio-activated topical ophthalmic pharmaceuticals that are designed to treat common refractive conditions, including presbyopia, low myopia and post-cataract refractive error.
In addition, Glaukos is developing a patented, non-invasive, transdermal drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and corneal disorders such as allergy, blepharitis, conjunctivitis and related conditions. Early human studies of this novel delivery system have demonstrated efficacy while limiting the side effects often associated with drugs delivered as topical eye drops. This novel drug delivery platform adds to several organic corneal health R&D initiatives we already have in place.